GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

their blood pressure improves—but their anti-hypertensive medications are never adjusted, so they faint or experience low ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Ozempic, Mounjaro, and other glucagon-like peptide-1 medications, otherwise known as GLP-1s, are changing how Americans shop for groceries. In early January, Food & Wine published a story about ...

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight ...

“I’m making money to afford semagultide,” Rice, 42, who works three jobs to afford the expensive injectables, explained to her over 14,000 TikTok fans . Classified as a GLP-1, appetite-suppressing ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...